GH Stock Recent News

On Thursday, Guardant Health GH reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the consensus loss of 74 cents.

Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Bill Bonello - Craig-Hallum Tycho Peterson - Jefferies Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Mark Massaro - BTIG Patrick Donnelly - Citi Dan Arias - Stifel Tejas Savant - Morgan Stanley Rachel Vatnsdal - JPMorgan Kyle Mikson - Canaccord Mason Carrico - Stephens Inc. Matt Sykes - Goldman Sachs Operator Good afternoon. Thank you for attending today's Guardant Health Q4 2024 Earnings Call.

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Guardant Health (GH) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.58 per share a year ago.

Guardant Health (GH -3.26%), a leader in precision oncology testing, announced its fourth-quarter results on Feb. 20. Total revenue rose 30% year over year to $201.8 million, outpacing analysts' consensus estimates of $192 million.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Guardant Health (GH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Blood-based cancer testing presents a large opportunity, that is now being realized, with the proliferation of MRD and screening tests. While there is significant competition, and the market winners are yet to be determined, Guardant Health is well positioned. Guardant has faced skepticism due to its large losses and the questionable efficacy of blood-based CRC screening tests.

After losing some value lately, a hammer chart pattern has been formed for Guardant Health (GH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.